Crescent Biopharma, Inc.
CBIO Healthcare Biotechnology
Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023. In the quarter to June 2026, revenue grew 1,038,900.0%, EPS grew 85.0% and free cash flow fell 7.04%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CBIO
Crescent Biopharma, Inc. (CBIO) EV/Sales
As of 16 October 2026, Crescent Biopharma, Inc. (CBIO) trades at a EV/Sales of 187×. Over the past ten years it has ranged from −461× (February 2026) to 1,001× (January 2024); the current reading is higher than 81% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −291× | — |
| FY2023 | 729× | 24.42% |
| FY2022 | 586× | — |
| FY2021 | −13.1× | — |
| FY2020 | 3.6× | 36.07% |
| FY2016 | 2.7× | 50.83% |
| FY2015 | 1.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 334× | — |
| Jun 2022 | −159× | — |
| Dec 2021 | −13.1× | — |
| Sep 2021 | 9.3× | 862.53% |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ARVN Arvinas, Inc. compare | −0.4× |
| NGNE Neurogene Inc. compare | n/m |
| RGNX REGENXBIO Inc. compare | 1.5× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 2.6× |
| ALLO Allogene Therapeutics, Inc. compare | 20.9× |
| OCS Oculis Holding AG compare | 109× |
| CBIO Crescent Biopharma, Inc. | 187× |
| ALT Altimmune, Inc. compare | 2,534× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)